Patents by Inventor Allison COLTHART

Allison COLTHART has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230399415
    Abstract: A Twin Immune Cell Engager (TWICE) is a kit or composition for treating cancer comprising a first component and second component. Each component comprises a targeting moiety that binds a tumor antigen expressed by the cancer or an antigen expressed by a non-cancer cell in the tumor microenvironment. In some embodiments, the first and second components each comprise an immune cell binding domain capable of immune cell binding activity when binding the immune cell binding domain in the other component, and a complementary binding domain capable of binding to a complementary antigen when binding the complementary binding domain in the other component. In some embodiments, the first and/or second components comprise a complementary functional domain with activity when targeted to the cancer cell or its microenvironment. The present TWICE complexes offer a unique ability to combine multiple functions into a two-component complex that becomes activated in the tumor microenvironment.
    Type: Application
    Filed: May 31, 2023
    Publication date: December 14, 2023
    Applicant: Revitope Limited
    Inventors: Martin PREYER, Allison COLTHART, Pamela WEINSTEIN, Patrick WIENCEK, Emma GEIGER, Werner MEIER
  • Patent number: 11702482
    Abstract: A Twin Immune Cell Engager (TWICE) is a kit or composition for treating cancer comprising a first component and second component. Each component comprises a targeting moiety that binds a tumor antigen expressed by the cancer or an antigen expressed by a non-cancer cell in the tumor microenvironment. In some embodiments, the first and second components each comprise an immune cell binding domain capable of immune cell binding activity when binding the immune cell binding domain in the other component, and a complementary binding domain capable of binding to a complementary antigen when binding the complementary binding domain in the other component. In some embodiments, the first and/or second components comprise a complementary functional domain with activity when targeted to the cancer cell or its microenvironment.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: July 18, 2023
    Assignee: Revitope Limited
    Inventors: Martin Preyer, Allison Colthart, Pamela Weinstein, Patrick Wiencek, Emma Geiger, Werner Meier
  • Publication number: 20220323600
    Abstract: The present disclosure provides targeted T-cell engaging agents (TEAC) and antibody tumor-targeting assembly complexes (ATTAC) for targeting to cancer. The TEAC or ATTAC described herein may have, for example, longer half-life or comprise multiple components in a single agent.
    Type: Application
    Filed: April 23, 2020
    Publication date: October 13, 2022
    Inventors: Mark Cobbold, Martin Preyer, Allison Colthart
  • Publication number: 20200190213
    Abstract: A Twin Immune Cell Engager (TWICE) is a kit or composition for treating cancer comprising a first component and second component. Each component comprises a targeting moiety that binds a tumor antigen expressed by the cancer or an antigen expressed by a non-cancer cell in the tumor microenvironment. In some embodiments, the first and second components each comprise an immune cell binding domain capable of immune cell binding activity when binding the immune cell binding domain in the other component, and a complementary binding domain capable of binding to a complementary antigen when binding the complementary binding domain in the other component. In some embodiments, the first and/or second components comprise a complementary functional domain with activity when targeted to the cancer cell or its microenvironment. The present TWICE complexes offer a unique ability to combine multiple functions into a two-component complex that becomes activated in the tumor microenvironment.
    Type: Application
    Filed: December 16, 2019
    Publication date: June 18, 2020
    Inventors: Martin PREYER, Allison COLTHART, Pamela WEINSTEIN, Patrick WIENCEK, Emma GEIGER, Werner MEIER